Charles River Laboratories International, Inc.’s stock price soars to $165, marking a bullish +6.87% leap

Charles River Laboratories International, Inc. (CRL)

165.00 USD +10.61 (+6.87%) Volume: 1.98M

Charles River Laboratories International, Inc.’s stock price is currently standing at 165.00 USD, experiencing a robust growth of +6.87% in today’s trading session with a substantial trading volume of 1.98M. Despite this positive momentum, the stock has seen a year-to-date decrease of -10.43%, reflecting its volatile performance in the market.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories (CRL) has been making headlines recently as Evercore ISI cut its stock target to $175. Despite facing political headwinds, the company reported better-than-expected sales in Q4, exceeding revenue estimates. Additionally, Charles River announced layoffs at its Memphis cell therapy manufacturing site. The company’s Q4 earnings call revealed a revenue of $1.00 billion and $2.66 non-GAAP EPS, beating expectations. However, William Blair recently downgraded the stock rating to Market Perform. With FY25 EPS projected at $9.10-$9.60, Charles River Laboratories continues to navigate challenges while striving for growth.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Charles River Laboratories International, Inc. is projected to have a positive long-term outlook based on its Smartkarma Smart Scores. With a high score in Value and Growth, the company is seen as having strong potential for future performance and profitability. Despite lower scores in Dividend and Resilience, Charles River Laboratories‘ focus on providing research tools and support services for drug discovery and development positions it well in the market.

Although Charles River Laboratories may face challenges in terms of Dividend and Resilience, its overall outlook remains promising due to its strong Value and Growth scores. The company’s dedication to providing essential animal research models for pharmaceutical and biotechnology companies, hospitals, and academic institutions sets it apart in the industry. With a moderate Momentum score, Charles River Laboratories is poised for continued success in the field of drug development and research.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma